Gut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions
Authors:
- Samuel Oluwadare OlalekanSOSamuel Oluwadare Olalekan
- Patrick Godwin OkwutePOPatrick Godwin Okwute
- Ifabunmi Oduyemi OsonugaIOIfabunmi Oduyemi Osonuga
- Adekunle Muiz MofolorunsoAMAdekunle Muiz Mofolorunso
- Bukunola Oluyemisi AdegbesanBABukunola Oluyemisi Adegbesan
- Esther Nkechi EzimaEEEsther Nkechi Ezima
- Gideon Olamilekan OluwatunaseGOGideon Olamilekan Oluwatunase
Open Access
- 3 June 2025
- book chapter
- Published by IntechOpen
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.Keywords
This publication has 59 references indexed in Scilit:
- Fecal Microbiota Transplantation for Treatment of Parkinson DiseaseJAMA Neurology, 2024
- Cold‐pressed perilla seed oil: Investigating its protective influence on the gut–brain axis in mice with rotenone‐induced Parkinson's diseaseFood Science & Nutrition, 2024
- The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson’s DiseaseMolecular Neurobiology, 2024
- The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic ApplicationsCNS Drugs, 2024
- Dietary intake of α-ketoglutarate ameliorates α-synuclein pathology in mouse models of Parkinson’s diseaseCellular and Molecular Life Sciences, 2023
- Ketogenic diet protects MPTP‐induced mouse model of Parkinson's disease via altering gut microbiota and metabolitesMedcomm, 2023
- Neuroprotective and Immunomodulatory Effects of Probiotics in a Rat Model of Parkinson’s DiseaseNeurotoxicity Research, 2023
- Premotor, nonmotor and motor symptoms of Parkinson's Disease: A new clinical state of the artAgeing Research Reviews, 2022
- Proinflammatory IL-17 levels in serum/cerebrospinal fluid of patients with neurodegenerative diseases: a meta-analysis studyNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- Vancomycin Pretreatment on MPTP-Induced Parkinson’s Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and GutJournal of Neuroimmune Pharmacology, 2022